U.S. Markets open in 4 hrs 58 mins
  • Gold

    1,788.20
    -5.20 (-0.29%)
     
  • EUR/USD

    1.1596
    -0.0007 (-0.0580%)
     
  • 10-Yr Bond

    1.6190
    0.0000 (0.00%)
     
  • Vix

    15.82
    +0.58 (+3.81%)
     
  • GBP/USD

    1.3731
    -0.0032 (-0.2334%)
     
  • USD/JPY

    113.7730
    -0.3560 (-0.3119%)
     
  • BTC-USD

    59,118.14
    -3,823.49 (-6.07%)
     
  • CMC Crypto 200

    1,419.85
    -85.30 (-5.67%)
     
  • FTSE 100

    7,263.88
    -13.74 (-0.19%)
     
  • Nikkei 225

    29,098.24
    -7.76 (-0.03%)
     

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of DKNG, BZ and CRMD

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·3 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

NEW YORK, NY / ACCESSWIRE / August 30, 2021 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.

DraftKings Inc. f/k/a Diamond Eagle Acquisition Corp. (NASDAQ:DKNG)
Class Period: December 23, 2019 - June 15, 2021
Lead Plaintiff Deadline: August 31, 2021

According to the complaint, DraftKings Inc. f/k/a Diamond Eagle Acquisition Corp. allegedly made materially false and/or misleading statements and/or failed to disclose that: (i) SBTech Global Limited ("SBTech"), a company acquired by DraftKings, had a history of unlawful operations; (ii) accordingly, DraftKings' merger with SBTech exposed the Company to dealings in black-market gaming; (iii) the foregoing increased the Company's regulatory and criminal risks with respect to these transactions; (iv) as a result of all the foregoing, the Company's revenues were, in part, derived from unlawful conduct and thus unsustainable; (v) accordingly, the benefits of the Business Combination were overstated; and (vi) as a result, the Company's public statements were materially false and misleading at all relevant times.

Learn about your recoverable losses in DKNG: https://www.kleinstocklaw.com/pslra-1/draftkings-inc-f-k-a-diamond-eagle-acquisition-corp-loss-submission-form?id=19117&from=1

Kanzhun Limited (NASDAQ:BZ)
Class Period: June 11, 2021 - July 2, 2021
Lead Plaintiff Deadline: September 10, 2021

Kanzhun Limited allegedly made materially false and/or misleading statements and/or failed to disclose that: (1) Kanzhun would face an imminent cybersecurity review by the Cyberspace Administration of China ("CAC"); (2) the CAC would require Kanzhun to suspend new user registration on its BOSS Zhipin app; (3) Kanzhun needed to "to conduct a comprehensive examination of cybersecurity risks"; (4) Kanzhun needed to "enhance its cybersecurity awareness and technology capabilities"; and (5) as a result, Defendants' statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.

Learn about your recoverable losses in BZ: https://www.kleinstocklaw.com/pslra-1/kanzhun-limited-loss-submission-form?id=19117&from=1

CorMedix Inc. (NASDAQ:CRMD)
Class Period: July 8, 2020 - May 13, 2021
Lead Plaintiff Deadline: September 20, 2021

The CRMD lawsuit alleges that CorMedix Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) deficiencies existed with respect to an investigational drug product, DefenCath's, manufacturing process and/or at the facility responsible for manufacturing DefenCath; (ii) in light of the foregoing deficiencies, the Food and Drug Administration was unlikely to approve the DefenCath new drug application for catheter-related bloodstream infections in its present form; (iii) Defendants had downplayed the true scope of the deficiencies with DefenCath's manufacturing process and/or at the facility responsible for manufacturing DefenCath; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.

Learn about your recoverable losses in CRMD: https://www.kleinstocklaw.com/pslra-1/cormedix-inc-loss-submission-form?id=19117&from=1

Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.

J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
jk@kleinstocklaw.com
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com

SOURCE: The Klein Law Firm



View source version on accesswire.com:
https://www.accesswire.com/662004/The-Klein-Law-Firm-Reminds-Investors-of-Class-Actions-on-Behalf-of-Shareholders-of-DKNG-BZ-and-CRMD